The most widely used models for predicting heart failure rely on a complex combination of lifestyle, demographic, and cardiovascular risk factor information.
But today Dr. Vijay Nambi, assistant professor of medicine – section of cardiovascular research and a staff cardiologist at Ben Taub Hospital, and Dr. Christie Ballantyne, professor of medicine, section chief of cardiology and cardiovascular research in the Department of Medicine and of The Methodist Hospital Center for Cardiovascular Disease Prevention, presented new data that show two biomarkers can improve heart failure risk prediction when used as part of a simpler model. Their presentation was part of the American Heart Association's Scientific Sessions 2012 in Los Angeles.
Nambi and Ballantyne said their simpler model could use information from lab reports to assess heart failure risk, and could be useful to both patients and doctors.
Nambi and Ballantyne's model uses age, race, and the blood concentrations of two blood biomarkers -- troponin T and NT-proBNP -- to show whether or not a patient is at elevated risk for heart failure.
Applying the model to patient data from the ongoing ARIC study (Atherosclerosis Risk in Communities), the researchers found their simple heart failure risk model was comparable to more complex models that take into account age, race, systolic blood pressure, antihypertensive medication use, smoking or former smoking, diabetes, body-mass index, prevalent coronary heart disease and heart rate.
The protein troponin T is part of the troponin complex and is traditionally used in the diagnosis of heart attacks. NT-proBNP is an inactive peptide fragment left over from the production of brain natriuretic peptide (BNP), a small neuropeptide hormone that has been shown to have value in diagnosing recent and ongoing congestive heart failure The researchers used both these markers in the prediction of future heart failure (over 10 years) thereby understanding which individuals among a general population are at the highest risk of heart failure. Finally, they showed that adding these markers to the existing models resulted in the best risk prediction models.
This is preliminary data. The ARIC study is administered by the National Heart, Lung, and Blood Institute.
Ballantyne is also the director of the Maria and Alando J. Ballantyne Atherosclerosis Clinical Research Laboratory at BCM and director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart Center and co-director of the Lipid Metabolism and Atherosclerosis Clinic at The Methodist Hospital.